SXTP

Travelers can now purchase the only once-weekly, broad-spectrum malaria preventive online, through the Runway Health telehealth platform WASHINGTON, April 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced ARAKODA® (tafenoquine) for malaria prevention is now available for purchase on the Runway Health website, for U.S. travelers seeking more convenient protection against malaria before visiting endemic regions. Patients can now conveniently connect with a licensed healthcare professional on Runway Health, who will

FY 2025 net product revenues increased 65% to $1,005,000Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the 2025 fiscal year ended December 31, 2025. Financial Highlights for the Fiscal Year Ended December 31, 2025: Net product revenues increased 65% from $607.6 thousand in 2024 to $1.0 million in 2025, driven by rising sales, price increases, and fewer returns.The Company achieved a gross profit of approximat

10-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

FDA has until May 25, 2026 to object to the notification, after which the Company will be free to market its proposed dietary supplement containing Australian Chestnut ExtractCompany has signed an option agreement with Florida State University (FSU) to license a capsule formulation, expanding on its recent exercise of a license option for large-scale production WASHINGTON, March 18, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced it submitted a New Dietary Ingredient Notification (NDIN) to the U.S. Food and Drug Admi

424B5 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

424B5 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publicationCompany calls for existing babesiosis treatment guidelines to be reviewed in light of the new data WASHINGTON, March 11, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that three of three enrolled patients have been cured of babesiosis after completing the tafenoquine regimen in the Company's trial of relapsing babesiosis in immunosuppressed patients. The Com

424B5 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine)Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company's marketing strategyPartnership will improve the affordability of ARAKODA at over 70,000 pharmacies nationwide for people planning travel to malaria-endemic regions WASHINGTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced a partnership with GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., to offer eligible co

WASHINGTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced it has exercised the option in its agreement with Florida State University (FSU) to negotiate an exclusive license to use large-scale purification techniques to extract castanospermine from the seeds of Castanospermum australe (commonly known as the Australian Chestnut, the Moreton Bay Chestnut, and the Black Bean Tree). Castanospermum australe grows primarily in the Australian states of Queensland and New South Wales, but also in Florida, Hawaii, a

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

Partnership adds a travel-focused consumer telehealth platform to the ARAKODA® marketing strategy, offering a new convenience to people planning travel to malaria-endemic regions of the worldARAKODA is the only FDA-approved, broad spectrum, once-weekly malaria prevention option for international travelers WASHINGTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced a partnership with Runway Health to expand pre-departure access to ARAKODA® (tafenoquine) for prevention of malaria among international traveler

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it will effect a one-for-four (1:4) reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on January 20, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). 60 Degrees Pharma has requested that its Common Stock begin trading on January 20, 2026, on a post-reverse split basis on the Nasdaq under the existing symbo

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA® (tafenoquine) for treatment of chronic babesiosisData support theory among specialists that Babesia infection may prolong recovery times in patients with chronic fatigue WASHINGTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that infection with Babesia, a parasite that causes the emerging tick-borne illness called babesiosis, was found in 24 percent of a cohort of 50 patients with chronic fatigue in a stu

4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

6-month commercial pilot demonstrated increasing demand among prescribersExpansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing campaignAdditional clinical sites in ongoing babesiosis treatment trials will be initiated in light of FDA feedback regarding Company's breakthrough therapy designation request WASHINGTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today the planned expansion of the Company's sales and marketing initiatives after encour

90-day trial will measure change in general fatigue in patients with chronic babesiosis following tafenoquine treatmentStudy will run approximately 12 months and enroll up to 100 patientsInternal estimates of the unmet medical need are between 4,400 and 190,000 cases annually, with no existing FDA-approved treatment for babesiosis WASHINGTON, Nov. 21, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the central study site for the Company's B-FREE Chronic Babesiosis Study, the Cohen Center for Recovery from Comple

SCHEDULE 13G/A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)